Avidity Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Avidity Biosciences generated cash of -$119,064,000, which is more than the previous year. Cash used in financing activities reached the amount of $93,864,000 last year. Net change in cash is therefore -$155,270,000.
Cash Flow
| 2018 | -9.65M | -49K | 5.14M |
|---|---|---|---|
| 2019 | 2.49M | -235K | 89.23M |
| 2020 | -37.11M | -7.78M | 272.03M |
| 2021 | -94.81M | -82.51M | 176.31M |
| 2022 | -136.26M | -189.95M | 346.17M |
| 2023 | -119.06M | -130.07M | 93.86M |
RNA Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 340.64M | 320.69M | 321.71M | 94.57M | 3.09M | 7.65M |
Operating activities | ||||||
Net income | -212.22M | -173.99M | -118.00M | -44.35M | -24.73M | -11.21M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 2.10M | 1.38M | 639K | 373K | 348K | 383K |
Stock-based compensation expense | 38.22M | 27.13M | 17.05M | 4.31M | 406K | 0 |
| Deferred income tax benefit | 38.22M | 27.13M | 17.05M | 4.31M | 406K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.76M | 18.31M | 6.04M | 5.74M | 451K | 780K |
Cash generated by operating activities | -119.06M | -136.26M | -94.81M | -37.11M | 2.49M | -9.65M |
Investing activities | ||||||
Purchases Of Investments | -461.00M | -355.83M | -85.35M | -6.69M | 0 | 0 |
Investments In Property Plant And Equipment | -4.22M | -2.82M | -3.74M | -1.09M | -235K | -49K |
Acquisitions Net | 0 | 187.13M | 82.51M | 0 | 0 | 0 |
Cash generated by investing activities | -130.07M | -189.95M | -82.51M | -7.78M | -235K | -49K |
Financing activities | ||||||
Common Stock Issued | 60.54M | 344.77M | 176.31M | 276.72M | 65K | 162K |
Payments for dividends | 0 | 0 | 0 | 0 | -106K | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -4.68M | 16.65M | -4.98M |
Cash used in financing activities | 93.86M | 346.17M | 176.31M | 272.03M | 89.23M | 5.14M |
Net Change In Cash | -155.27M | 19.94M | -1.01M | 227.13M | 91.48M | -4.56M |
Cash at end of period | 185.37M | 340.64M | 320.69M | 321.71M | 94.57M | 3.09M |
| Data source | Data source | Data source | Data source |